Abstracts

REAL-WORLD EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR HEPATITIS C VIRUS INFECTION

Glecaprevir and pibrentasvir (GLE/PIB) are direct-acting antiviral agents (DAAs) with pan-genotypic activity and a high barrier to resistance. We evaluated the effectiveness and safety of GLE/PIB in a large prospective registry HCV-infected individuals with/without coinfection by HIV and receiving DAAs for HCV infection. RUA-VHC (Madrid Registry of Use of DAA for HCV) is a prospective…

BARRIERS TO DIRECTLY ACTING ANTIVIRALS THERAPY AMONG HIV/HCV-COINFECTED ADULTS

HIV and chronic hepatitis C virus (HCV) coinfection carries substantial risk for all-cause mortality and liver-related morbidity and mortality; yet many people co-infected with HIV/HCV remain untreated for HCV infection. We explored demographic, clinical variables and social determinants of health among coinfected participants in routine HIV care that may differentiate those treated versus untreated with…

RESISTANCE ANALYSIS IN HCV-3–INFECTED PATIENTS WITHIN THE ITALIAN NETWORK VIRONET-C

This study aimed to investigate the presence and role of resistance-associated-substitutions (RASs) in HCV genotype 3 (GT3). Within the Italian VIRONET-C network, a total of 539 GT3 infected patients (pts, 417 DAA-naïve and 135 DAA-failures, of them,13 at both baseline [BL] and failure), were analysed. Sanger-sequencing of NS3/NS5A/NS5B was performed by home-made protocols. The majority…

MEDICAID HCV TREATMENT RESTRICTIONS: SPILLOVER TO THE PRIVATE-PAYER HCV CARE CASCADE?

Medicaid HCV treatment restrictions limit access to HCV cure. There is evidence that public insurance policies influence care more broadly, even among commercially insured patients. Further, if states limit HCV treatment access, screening may lag due to decreased provider motivation. This study investigates whether Medicaid HCV treatment restrictions ‘spillover’ to affect HCV testing among patients with…

SYNDEMIC OF VIRAL COINFECTIONS AND INCIDENT END-STAGE RENAL DISEASE

Advances in infection care and treatment have improved the life expectancy of persons living with HIV. Consequently, persons living with HIV are aging with increased risk of chronic conditions such as liver and cardiovascular diseases, lung cancer, neurocognitive impairment and chronic kidney disease (CKD). Syndemic viral infections are associated with increased risk of CKD and…